Equity Profile

RGEN

Repligen Corporation

Health CareLife Sciences Tools & Services$8.2B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Repligen Corporation (RGEN) operates in the health care sector, specifically within life sciences tools and services. The company is important as it provides critical technologies and products that support biopharmaceutical manufacturing, which is essential for producing therapies and vaccines.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well Repligen is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is crucial for understanding the demand for Repligen's products and services, especially in a competitive market.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, surpassing expectations by 25%. The stock reacted positively, gaining over 6% the following day.

Management Promises & Guidance

Focus on expanding product offerings in bioprocessing.
Commitment to improving operational efficiencies.
Plans to enhance customer support and service capabilities.

Expectations

Wall Street Expectations

Investors are generally optimistic about Repligen's upcoming earnings, especially given its strong track record of beating EPS estimates. However, there is uncertainty regarding revenue growth and overall market conditions.

Bull Case

If Repligen continues its trend of exceeding EPS estimates, it could lead to increased investor confidence and a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given the recent volatility in the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Repligen's history of beating EPS estimates, the actual EPS figure will be crucial in determining market sentiment post-earnings.

What is the outlook for revenue growth in the bioprocessing segment?

Revenue growth in this key area will indicate the company's ability to capture market demand and sustain its competitive edge.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Repligen's ability to sustain its growth trajectory, especially given its recent performance and market position.

Supporting Evidence

Repligen has consistently beaten EPS estimates, suggesting strong operational management.

The options market is pricing a smaller move than historical averages, indicating potential for a surprise.

Recent trends in biopharmaceutical demand could drive unexpected revenue growth.

Key Risk

If the EPS comes in below $0.40, it could significantly undermine the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued growth against the backdrop of economic uncertainty and competitive pressures.

Bull Confirmed If

An EPS of $0.50 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.40 would support the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move of about 4.1%, suggesting that traders are anticipating some volatility around the earnings announcement.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests a stock increase of around 3.95%, confirming positive market sentiment.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors await further commentary from management.

Miss

If the company misses expectations, the stock could decline by approximately 4.72%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in bioprocessing.
2Insights into customer demand trends and market conditions.
3Management's commentary on operational efficiencies and cost management.
4Guidance on revenue expectations for the next quarter.
5Any strategic partnerships or collaborations that may impact growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge how well Repligen is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is crucial for understanding the demand for Repligen's products and services, especially in a competitive market.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, surpassing expectations by 25%. The stock reacted positively, gaining over 6% the following day.

Management Promises & Guidance

Focus on expanding product offerings in bioprocessing.
Commitment to improving operational efficiencies.
Plans to enhance customer support and service capabilities.

Expectations

Wall Street Expectations

Bull Case

If Repligen continues its trend of exceeding EPS estimates, it could lead to increased investor confidence and a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given the recent volatility in the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Repligen's history of beating EPS estimates, the actual EPS figure will be crucial in determining market sentiment post-earnings.

What is the outlook for revenue growth in the bioprocessing segment?

Revenue growth in this key area will indicate the company's ability to capture market demand and sustain its competitive edge.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Repligen's ability to sustain its growth trajectory, especially given its recent performance and market position.

Supporting Evidence

Repligen has consistently beaten EPS estimates, suggesting strong operational management.

The options market is pricing a smaller move than historical averages, indicating potential for a surprise.

Recent trends in biopharmaceutical demand could drive unexpected revenue growth.

Key Risk

If the EPS comes in below $0.40, it could significantly undermine the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued growth against the backdrop of economic uncertainty and competitive pressures.

Bull Confirmed If

An EPS of $0.50 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $0.40 would support the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move of about 4.1%, suggesting that traders are anticipating some volatility around the earnings announcement.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations, history suggests a stock increase of around 3.95%, confirming positive market sentiment.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors await further commentary from management.

Miss

If the company misses expectations, the stock could decline by approximately 4.72%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in bioprocessing.
2Insights into customer demand trends and market conditions.
3Management's commentary on operational efficiencies and cost management.
4Guidance on revenue expectations for the next quarter.
5Any strategic partnerships or collaborations that may impact growth.